KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vir Biotechnology (VIR) Operating Expenses (2018 - 2025)

Historic Operating Expenses for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to $173.7 million.

  • Vir Biotechnology's Operating Expenses fell 2567.61% to $173.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $565.4 million, marking a year-over-year decrease of 1777.53%. This contributed to the annual value of $661.4 million for FY2024, which is 1416.19% down from last year.
  • According to the latest figures from Q3 2025, Vir Biotechnology's Operating Expenses is $173.7 million, which was down 2567.61% from $119.6 million recorded in Q2 2025.
  • In the past 5 years, Vir Biotechnology's Operating Expenses registered a high of $241.0 million during Q4 2021, and its lowest value of $116.1 million during Q2 2021.
  • Over the past 5 years, Vir Biotechnology's median Operating Expenses value was $173.7 million (recorded in 2025), while the average stood at $175.0 million.
  • In the last 5 years, Vir Biotechnology's Operating Expenses soared by 11881.19% in 2021 and then crashed by 3386.4% in 2024.
  • Over the past 5 years, Vir Biotechnology's Operating Expenses (Quarter) stood at $241.0 million in 2021, then decreased by 17.05% to $199.9 million in 2022, then dropped by 22.06% to $155.8 million in 2023, then fell by 16.87% to $129.5 million in 2024, then surged by 34.09% to $173.7 million in 2025.
  • Its Operating Expenses was $173.7 million in Q3 2025, compared to $119.6 million in Q2 2025 and $142.6 million in Q1 2025.